Thomas Edward Hamilton

Director

Thomas Edward Hamilton (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Larimar Therapeutics, Inc. (LRMR). Across 2 priced purchase filings, the average 21-session return was +2.2% from execution and +2.8% from disclosure (delay-adjusted; derived). The largest single filing was $500K of LRMR (100,000 sh × $5.00, as filed), executed Feb 27.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+2.2%

avg across 2 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+2.8%

same 2 filings, from disclosure

Filings, ttm

2 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$667K

shares × price, as filed

Last traded

Jul 6

Filed Jul 8

Median ADV $8.5M across their filed names

Open performance→

Volume by month

Buys $667K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

LRMR

Larimar Therapeutics, Inc. LRMR · 2 buys · 0 sells 2 filings

Recent filings

LRMRPURCHASE Larimar Therapeutics, Inc. View filing → $167K
50,000 sh × $3.34
Exec Jul 6
Filed Jul 8 · 4:05 PM ET LRMRPURCHASE Larimar Therapeutics, Inc. View filing → $500K
100,000 sh × $5.00
Exec Feb 27
Filed Mar 2 · 4:30 PM ET